CINECA IRIS Institutional Research Information System

MARINO', MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.637
AS - Asia 6.037
EU - Europa 5.104
SA - Sud America 1.018
AF - Africa 302
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 5
Totale 26.111
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.279
SG - Singapore 1.975
CN - Cina 1.642
IT - Italia 1.573
HK - Hong Kong 1.209
SE - Svezia 1.018
BR - Brasile 855
DE - Germania 583
BG - Bulgaria 443
VN - Vietnam 365
GB - Regno Unito 350
CA - Canada 276
TR - Turchia 230
RU - Federazione Russa 212
FR - Francia 199
FI - Finlandia 188
IN - India 155
AT - Austria 141
UA - Ucraina 139
CI - Costa d'Avorio 114
KR - Corea 92
SN - Senegal 61
JP - Giappone 59
BD - Bangladesh 56
CH - Svizzera 48
IQ - Iraq 47
AR - Argentina 45
ZA - Sudafrica 44
SA - Arabia Saudita 38
MX - Messico 37
NL - Olanda 36
EC - Ecuador 34
PL - Polonia 31
BE - Belgio 30
ES - Italia 24
ID - Indonesia 19
UZ - Uzbekistan 19
CO - Colombia 17
PK - Pakistan 17
VE - Venezuela 17
DZ - Algeria 16
IE - Irlanda 16
NP - Nepal 15
MA - Marocco 14
PY - Paraguay 14
CL - Cile 12
AZ - Azerbaigian 11
CZ - Repubblica Ceca 11
EG - Egitto 11
PE - Perù 11
JO - Giordania 10
NG - Nigeria 10
AE - Emirati Arabi Uniti 9
GR - Grecia 9
LT - Lituania 9
AU - Australia 8
HU - Ungheria 8
BJ - Benin 7
GE - Georgia 7
JM - Giamaica 7
KE - Kenya 7
PH - Filippine 7
RO - Romania 7
CR - Costa Rica 6
IL - Israele 6
PA - Panama 6
TW - Taiwan 6
UY - Uruguay 6
BB - Barbados 5
IR - Iran 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
AL - Albania 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
EU - Europa 4
HR - Croazia 4
KG - Kirghizistan 4
LB - Libano 4
MY - Malesia 4
TN - Tunisia 4
EE - Estonia 3
KZ - Kazakistan 3
MD - Moldavia 3
OM - Oman 3
PT - Portogallo 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SR - Suriname 3
BH - Bahrain 2
BS - Bahamas 2
CG - Congo 2
DK - Danimarca 2
KH - Cambogia 2
KW - Kuwait 2
ML - Mali 2
MU - Mauritius 2
NI - Nicaragua 2
NO - Norvegia 2
Totale 26.087
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.460
Ashburn 1.443
Fairfield 1.218
Hong Kong 1.196
Ann Arbor 1.058
Singapore 1.042
Houston 969
Dallas 957
Santa Clara 784
Chandler 703
Seattle 504
Sofia 441
Milan 424
Shanghai 410
Beijing 395
Wilmington 387
Cambridge 380
New York 323
Serra 248
Ottawa 228
Boardman 208
Los Angeles 193
Princeton 186
Lawrence 173
Jacksonville 155
Munich 149
Medford 147
London 132
Vienna 125
Florence 118
Abidjan 114
Izmir 113
Hefei 109
Nanjing 97
Dong Ket 94
Seoul 89
Des Moines 85
Ho Chi Minh City 80
Istanbul 78
Bremen 75
Dearborn 73
Redondo Beach 72
Buffalo 69
Frankfurt am Main 64
San Diego 63
São Paulo 62
Marseille 61
Dakar 59
Nanchang 59
Pisa 55
Turku 54
Ogden 49
Rome 48
Tokyo 46
Bern 44
Hanoi 40
Jüchen 36
Redwood City 35
Düsseldorf 34
Lancaster 34
Chicago 31
Rio de Janeiro 31
Brussels 30
Kunming 30
Hebei 28
Norwalk 25
Denver 23
Baghdad 21
Shenyang 21
Atlanta 20
Changsha 20
Columbus 20
Fuzhou 20
Guangzhou 20
Vicopisano 20
Boulder 19
Brasília 19
Brooklyn 19
Chennai 19
Jiaxing 19
Poplar 19
The Dalles 19
Helsinki 18
San Francisco 18
Warsaw 18
San Jose 17
Montreal 16
Orem 16
Phoenix 16
Tashkent 16
Toronto 16
Washington 16
Jeddah 15
Johannesburg 15
Nuremberg 15
Stockholm 15
Lucca 14
Paris 14
Porto Alegre 14
Quanzhou 14
Totale 18.923
Salva come PNG Salva come JPEG
Nome #
Complicanze chirurgiche in pazienti sottoposti a decompressione orbitaria per oftalmopatia di Graves [Surgical complications in orbital decompression for Graves’ orbitopathy] 430
Thyroid directed antibodies 355
Natural history of graves’ orbitopathy after treatment 253
Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy 225
Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? 210
False negative results observed in anti-thyroid peroxidase autoantibody determination by competitive radioimmunoassays using monoclonal antibodies 205
Role of the underlying thyroid disease on the phenotype of graves' orbitopathy in a tertiary referral center 204
Sortilin is a putative post-endocytic receptor of thyroglobulin 202
Targeting of thyroglobulin to transcytosis following megalin-mediated endocytosis: evidence for a preferential ph-independent pathway 193
TSH-Dependent Expression of the LDL Receptor-Associated Protein (RAP) in Thyroid Epithelial Cells 190
High Serum Cholesterol Is a Novel Risk Factor for Graves' Orbitopathy: Results of a Cross-Sectional Study 189
Sequencing of the entire coding region of the receptor associated protein (RAP) in patients with primary hypothyroidism of unknown origin 186
Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts 184
TSH-Dependent expression of the LDL receptor-associated protein (RAP) in thyroid epithelial cells 183
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with graves’ ophthalmopathy 180
Effect of thyroglobulin autoantibodies on the metabolic clearance of serum thyroglobulin 180
Thyroglobulin Autoantibodies arise before Thyroperoxidase Autoantibodies in Juvenile Autoimmune Thyroiditis 179
Significance of low levels of thyroglobulin autoantibodies associated with undetectable thyroglobulin after thyroidectomy for differentiated thyroid carcinoma 178
Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases 177
Outcome of Graves' Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 176
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial 176
Circulating thyroglobulin transcytosed by thyroid cells is complexed with secretory components of its endocytic receptor megalin 175
Spontaneous improvement of untreated mild graves' ophthalmopathy: Rundle's curve revisited. 173
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study 172
Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves' orbitopathy (GO) 171
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 170
Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement 169
Serum antibodies against megalin (gp330) in patients with autoimmune thyroiditis 168
Autoimmune thyroid diseases in patients treated with alemtuzumab for multiple sclerosis: An example of selective anti-TSH-receptor immune response 168
Binding of thyroglobulin (Tg) to the low-density lipoprotein receptor-associated protein (RAP) during the biosynthetic pathway prevents premature Tg interactions with sortilin 167
Pathogenetic and clinical aspects of autoimmune thyroiditis 165
VARIABLES AFFECTING THE LONG TERM OUTCOME OF GRAVES' ORBITOPATHY FOLLOWING HIGH DOSE INTRAVENOUS GLUCOCORTICOID PULSE THERAPY IN PATIENTS NOT TREATED WITH ORBITAL RADIOTHERAPY 165
Occurrence of Graves’ Orbitopathy and of Graves’ hyperthyroidism after a trauma to the eye 165
Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy 165
Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: the hypothesis of Kriss revisited 164
Impaired Thyroglobulin (Tg) Secretion By FRTL-5 Cells Transfected With Soluble Receptor Associated Protein (RAP): Evidence For A Role Of RAP In The Tg Biosynthetic Pathway 162
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 162
Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' Orbitopathy 161
Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial 161
Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma 160
Orbit-Thyroid Relationship 160
Glycosaminoglycans provide a binding site for thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy 160
Effect of thyroglobulin autoantibodies on the clearance of serum thyroglobulin in humans 159
Role of thyroglobulin endocytic pathways in the control of thyroid hormone release 158
Dissecting the genetic susceptibility to graves' disease in a cohort of patients of Italian origin 158
A case of drug-induced Graves’ Orbitopathy after combination therapy with Tremelimumab and Durvalumab 157
A treatment strategy for Graves' orbitopathy 156
IgM thyroglobulin autoantibodies are detectable in serum of patients with subacute thyroiditis 155
Role of the mononuclear cell infiltrate in Graves’ orbitopathy (GO): results of a large cohort study 154
Does Graves' Orbitopathy Ever Disappear? Answers to an Old Question 153
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 153
BINDING, UPTAKE AND DEGRADATION OF INTERNALIZED THYROGLOBULIN IN CULTURED THYROID AND NON THYROID CELLS 152
DEFECTIVE THYROGLOBULIN (Tg) STORAGE IN LDL RECEPTOR ASSOCIATED PROTEIN (RAP) DEFICIENT MICE 151
Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide: another molecular basis for the effects of selenium in graves’ orbitopathy 150
Selenium in the Treatment of Thyroid Diseases 150
Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy 150
Choroidal vascularity index in thyroid-associated ophthalmopathy: a cross-sectional study 149
Megalin-mediated transcytosis of thyroglobulin by thyroid cells is a calmodulin-dependent process 148
Outcome of Graves’ Orbitopathy after Total Thyroid Ablation and Glucocorticoid Treatment: Follow-Up of a Randomized Clinical Trial 148
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves 148
Circulating thyroid autoantibodies in a sample of Italian octo-nonagenarians: relationship to age, sex, disability, and lipid profile 147
Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy 147
Identification of a heparin-binding region of rat thyroglobulin involved in megalin binding 146
Thyroid volume and severity of graves' orbitopathy 146
Acute liver damage following intravenous glucocorticoid treatment for Graves’ ophthalmopathy 146
Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? 145
Megalin (gp330): a putative endocytic receptor for thyroglobulin (Tg) 145
Binding of heparin to human thyroglobulin (Tg) involves multiple binding sites including a region corresponding to a binding site of rat Tg 145
Binding of the low density lipoprotein receptor associated protein (RAP) to thyroglobulin (Tg): putative role of RAP in the Tg secretory pathway 145
Kidney abnormalities in low density lipoprotein receptor associated protein knockout mice 144
Cytokines in thyroid autoimmune infiltrate 143
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 143
Intracellular retention of thyroglobulin in the absence of the low-density lipoprotein receptor-associated protein (RAP) is likely due to premature binding to megalin in the biosynthetic pathway 143
PREGO ( presentation of Graves' orbitopathy) study: Changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012 142
Binding of rat thyroglobulin to heparan sulfate proteoglycans 141
Mechanistic Pathways of Selenium in the Treatment of Graves' Disease and Graves' Orbitopathy 141
Thyroid dysfunction in megalin deficient mice 140
ABSENCE OF PRIMARY HYPOTHYROIDISM AND GOITER IN SLC26A4 (-/-) MICE FED ON A LOW IODINE DIET 139
Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial 139
Increased frequency of euthyroid ophthalmopathy in patients with Graves' disease associated with myasthenia Gravis 139
Effects of total thyroid ablation vs near-total thyroidectomy alone on mild to moderate Graves' Orbitopathy treated with intravenous glucocorticoids 138
Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study 138
Mild clinical expression of myasthenia gravis associated with autoimmune thyroid diseases-Authors response. Letters to the Editor 137
Prognostic factors 137
Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. 137
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy 136
Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis 136
Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey 135
In Graves' disease, thyroid autoantibodies and ultrasound features correlate with distinctive histological features 134
Rehabilitative orbital decompression for Graves' orbitopathy: risk factors influencing the new onset of diplopia in primary gaze, outcome, and patients' satisfaction 133
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study 133
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 133
A questionnaire survey on the management of Graves' orbitopathy in Europe 132
Outcome of orbital decompression for disfiguring proptosis in patients with Graves' orbitopathy using various surgical procedures. 132
Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients 132
Rehabilitative orbital decompression for Graves’ orbitopathy: results of a randomized clinical trial 132
Influences of thyroid diseases in diabetic pregnant women 129
Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? 129
Retinal, choroidal and optic disc analysis in patients with Graves' disease with or without orbitopathy 127
Phosphoinositide 3-kinase (pi3-k) inhibits megalin-mediated transcytosis of thyroglobulin across thyroid epithelial cells at a post-sorting level 126
Totale 16.219
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.721
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.721
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021922 0 0 0 0 0 71 106 137 122 146 126 214
2021/20222.177 37 100 45 197 395 254 59 103 179 230 85 493
2022/20232.519 281 374 212 203 237 316 13 189 479 16 168 31
2023/20241.749 208 205 211 129 246 309 62 59 24 28 106 162
2024/20256.173 41 209 104 285 615 647 456 291 664 781 713 1.367
2025/20264.485 533 941 1.045 739 700 527 0 0 0 0 0 0
Totale 26.473